Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Phone+1-801-2789769
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings DateN/A
OptionableNot Optionable
Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions
What is Co-Diagnostics' stock symbol?
Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."
What price target have analysts set for CODX?
1 brokers have issued 1-year price objectives for Co-Diagnostics' shares. Their forecasts range from $2.00 to $2.00. On average, they expect Co-Diagnostics' share price to reach $2.00 in the next year. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for Co-Diagnostics.
What is the consensus analysts' recommendation for Co-Diagnostics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Co-Diagnostics.
Has Co-Diagnostics been receiving favorable news coverage?
Media headlines about CODX stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Co-Diagnostics earned a news impact score of 1.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Co-Diagnostics' key competitors?
What other stocks do shareholders of Co-Diagnostics own?
Who are Co-Diagnostics' key executives?
Co-Diagnostics' management team includes the folowing people:
- Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 66)
- Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 42)
- Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 71)
When did Co-Diagnostics IPO?
(CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.
How do I buy shares of Co-Diagnostics?
Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Co-Diagnostics' stock price today?
One share of CODX stock can currently be purchased for approximately $1.18.
What is Co-Diagnostics' official website?
How can I contact Co-Diagnostics?
Co-Diagnostics' mailing address is 4049 S Highland Dr, SALT LAKE CITY, UT 84124-1664, United States. The company can be reached via phone at +1-801-2789769.
MarketBeat Community Rating for Co-Diagnostics (NASDAQ CODX)
MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote "Outperform" if you believe CODX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days.
